Kem Yenal, MD
Family Medicine · Phila, PANPI 1215913868
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,251 of the $20,199 with a category attached, or 75.5%. It is spread thinly across 40 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $10,147 and has fallen 94.6% since, to $547 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 478 payments — averaging $42.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$4K
- Novo Nordisk$2K
- Modernatx, Inc.$2K
- GSK$2K
- AstraZeneca$1K
- AbbVie$987
- plus $8K from 34 others
Across 2,944 payments — averaging $4267.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$10.8M
- Bavarian Nordic A/s$916K
- Pfizer$440K
- Astrazeneca UK Limited$232K
- Novavax Inc$115K
- AstraZeneca$27K
What the payments were for
- Speaking & faculty fees$3,02215%
- Travel & lodging$1,9059%
- Food & beverage$15,25176%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$3,914
- Ozempic$922
- TRELEGY ELLIPTA$684
- RYBELSUS$448
- FARXIGA$373
- VRAYLAR$368
- ELIQUIS$250
- Kerendia$246
- INJECTAFER$245
- LOKELMA$241
- Vascepa$239
- NURTEC ODT$238
- JARDIANCE$234
- ENTRESTO$231
- UZEDY$222
- UBRELVY$201
- XARELTO$127
- DEXCOM G7 GSS (161)$127
- DEXCOM STELO GLUCOSE BIOSENSOR$127
- FASENRA$125
How this compares
$20,199 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Phila
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.